Clinical trials: ABO Incompatibility
Haemolysis Neonatal
Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born
- Trial name
- IVIG (NCT03130517)
- Testing
- intravenous immunoglobulin
- Volunteers
- 30 people
- Sponsor
- Assiut University
Hematological Malignancies, Haploidentical Stem Cell Transplantation
Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation
the impact of donor-recipient ABO matching on outcome of peripheral blood stem cell haploidentical hematopoietic stem cell transplantation
- Trial name
- NCT05103995
- Testing
- no intervention
- Where
- 2 sites in China
- Volunteers
- 510 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Neonatal Jaundice From Other Specified Causes, ABO Incompatibility
The Role of Breastmilk and Serum Exosomes in Neonatal Jaundice Due to ABO Incompatibility
Neonatal jaundice is a major global health issue that can lead to serious complications and even death if not promptly treated. ABO incompatibility is a common cause of pathological neonatal jaundice, but there are currently no…
- Conditions
- Neonatal Jaundice From Other Specified Causes, ABO Incompatibility, ABO Hemolytic Disease
- Trial name
- NCT06502847
- Testing
- Exosome profile study
- Where
- Turkey (Türkiye)
- Volunteers
- 338 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
COVID-19, Blood Group Antigen Abnormality
ABO Blood Group Type Association With COVID-19 Severity
The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide.
- Conditions
- COVID-19, Blood Group Antigen Abnormality, Blood Group Incompatibilities, Diabetes Mellitus
- Trial name
- NCT05859958
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- Arrowhead Regional Medical Center
ABO Incompatibility, Hemolytic Disease of Newborn
Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
The purpose of this research study is to more accurately measure the amount of true red blood cell breakdown (hemolysis) in newborn babies with potentially problematic blood type mismatch with their mothers (ABO incompatibility)…
- Conditions
- ABO Incompatibility, Hemolytic Disease of Newborn, Neonatal Jaundice, Neonatal Hyperbilirubinemia
- Trial name
- NCT00917007
- Where
- 2 sites in United States
- Sponsor
- State University of New York - Upstate Medical University
Hyperbilirubinemia, Neonatal Indirect
The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia
This is a prospective, open-label, randomized controlled trial conducted at Lattakia University Hospital (Tishreen University), aiming to evaluate the efficacy of Ursodeoxycholic Acid (UDCA) as an adjuvant to triple phototherapy…
- Trial name
- UDCA-Neo (NCT07110987)
- Testing
- Phototherapy, ursodeoxycholic acid (UDCA)
- Where
- Syria
- Volunteers
- 70 people
- Sponsor
- Tishreen University Hospital
Kidney Transplant
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
- Trial name
- ABOi (NCT01095887)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Newborn Jaundice, Hyperbilirubinemia, Neonatal
White Cover & Massage Effects on Bilirubin and Phototherapy in ABO-Incompatible Newborns
This study aims to examine the effect of white cover and massage application on bilirubin levels and phototherapy duration in newborns with ABO incompatibility receiving phototherapy.
- Conditions
- Newborn Jaundice, Hyperbilirubinemia, Neonatal, ABO Incompatibility, Newborn Massage
- Trial name
- NCT06921330
- Testing
- white cover-newborn massage
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Karabuk University
Jaundice, Neonatal, Hyperbilirubinemia, Neonatal
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
It is normal for red blood cells to die, even in newborn babies. The waste from that is called bilirubin. The liver clears bilirubin out of the body.
- Trial name
- JASMINE_204 (NCT01887327)
- Testing
- Phototherapy, Stannsoporfin
- Where
- 18 sites in United States
- Volunteers
- 91 people
- Sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Lung Transplant, ABO Incompatibility
A2 to O Lung Transplants
Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting…
- Trial name
- NCT05581745
- Testing
- Blood group A2 donor to blood group O recipient lung transplant surgery
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Rh Incompatibility Reaction
Development a Rhesus Type Compatibility Test by Means of an Antibody Able to Recognize RH1 Antigen Grafted on a Biochip
Every year, several millions of red cell concentrates are transfused. For each of them, a pretransfusional compatibility test is performed.
- Trial name
- ABORDAGE (NCT02857075)
- Testing
- Blood donation
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
ABO Incompatibility, Liver Transplant Surgery
Study on the Clinical Outcomes of ABO-Incompatible Living Donor Liver Transplantation
Evaluate the postoperative survival rate and incidence of rejection in patients undergoing ABO-incompatible living donor liver transplantation; analyze the occurrence of secondary endpoint events such as postoperative vascular…
- Conditions
- ABO Incompatibility, Liver Transplant Surgery, Living Donor Liver Transplantation
- Trial name
- NCT07273448
- Volunteers
- 100 people
- Sponsor
- Zhi-Jun Zhu